NMRA

Neumora Therapeutics, Inc.

NMRA · CIK 0001885522 · Annual (10-K) · Last 2 years

Financial Trends

Revenue
20232024
Net Income−$244M
20232024
Operating CF−$183M
20232024
Free Cash Flow−$183M
20232024

Income Statement

MetricFY 2024FY 2023
Revenue
Cost of Revenue
Gross Profit
R&D Expense$0.2B$0.1B
SG&A Expense
Operating Income$-0.3B$-0.3B
Net Income$-0.2B$-0.2B
EPS (Basic)$-1.53$-3.63
EPS (Diluted)$-1.53$-3.63

Balance Sheet

MetricFY 2024FY 2023
Total Assets$0.3B$0.5B
Current Assets$0.3B$0.5B
Cash & Equivalents$0.1B$0.4B
Total Liabilities$0.0B$0.0B
Current Liabilities$0.0B$0.0B
Stockholders' Equity$0.3B$0.5B

Cash Flow Statement

MetricFY 2024FY 2023
Operating Cash Flow$-0.2B$-0.2B
Investing Cash Flow$-0.1B$0.1B
Capital Expenditures$0.0B$0.0B
Financing Cash Flow$0.0B$0.2B